Cargando…

The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules

The programmed cell death ligand protein 1 (PD-L1) is a member of the B7 protein family and consists of 290 amino acid residues. The blockade of the PD-1/PD-L1 immune checkpoint pathway is effective in tumor treatment. Results: Two pharmacophore models were generated based on peptides and small mole...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Yanwen, Li, Xuanyi, Yao, Hequan, Lin, Kejiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572691/
https://www.ncbi.nlm.nih.gov/pubmed/31137573
http://dx.doi.org/10.3390/molecules24101940
_version_ 1783427699574833152
author Zhong, Yanwen
Li, Xuanyi
Yao, Hequan
Lin, Kejiang
author_facet Zhong, Yanwen
Li, Xuanyi
Yao, Hequan
Lin, Kejiang
author_sort Zhong, Yanwen
collection PubMed
description The programmed cell death ligand protein 1 (PD-L1) is a member of the B7 protein family and consists of 290 amino acid residues. The blockade of the PD-1/PD-L1 immune checkpoint pathway is effective in tumor treatment. Results: Two pharmacophore models were generated based on peptides and small molecules. Hypo 1A consists of one hydrogen bond donor, one hydrogen bond acceptor, two hydrophobic points and one aromatic ring point. Hypo 1B consists of one hydrogen bond donor, three hydrophobic points and one positive ionizable point. Conclusions: The pharmacophore model consisting of a hydrogen bond donor, hydrophobic points and a positive ionizable point may be helpful for designing small-molecule inhibitors targeting PD-L1.
format Online
Article
Text
id pubmed-6572691
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65726912019-06-18 The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules Zhong, Yanwen Li, Xuanyi Yao, Hequan Lin, Kejiang Molecules Article The programmed cell death ligand protein 1 (PD-L1) is a member of the B7 protein family and consists of 290 amino acid residues. The blockade of the PD-1/PD-L1 immune checkpoint pathway is effective in tumor treatment. Results: Two pharmacophore models were generated based on peptides and small molecules. Hypo 1A consists of one hydrogen bond donor, one hydrogen bond acceptor, two hydrophobic points and one aromatic ring point. Hypo 1B consists of one hydrogen bond donor, three hydrophobic points and one positive ionizable point. Conclusions: The pharmacophore model consisting of a hydrogen bond donor, hydrophobic points and a positive ionizable point may be helpful for designing small-molecule inhibitors targeting PD-L1. MDPI 2019-05-20 /pmc/articles/PMC6572691/ /pubmed/31137573 http://dx.doi.org/10.3390/molecules24101940 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhong, Yanwen
Li, Xuanyi
Yao, Hequan
Lin, Kejiang
The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules
title The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules
title_full The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules
title_fullStr The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules
title_full_unstemmed The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules
title_short The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules
title_sort characteristics of pd-l1 inhibitors, from peptides to small molecules
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572691/
https://www.ncbi.nlm.nih.gov/pubmed/31137573
http://dx.doi.org/10.3390/molecules24101940
work_keys_str_mv AT zhongyanwen thecharacteristicsofpdl1inhibitorsfrompeptidestosmallmolecules
AT lixuanyi thecharacteristicsofpdl1inhibitorsfrompeptidestosmallmolecules
AT yaohequan thecharacteristicsofpdl1inhibitorsfrompeptidestosmallmolecules
AT linkejiang thecharacteristicsofpdl1inhibitorsfrompeptidestosmallmolecules
AT zhongyanwen characteristicsofpdl1inhibitorsfrompeptidestosmallmolecules
AT lixuanyi characteristicsofpdl1inhibitorsfrompeptidestosmallmolecules
AT yaohequan characteristicsofpdl1inhibitorsfrompeptidestosmallmolecules
AT linkejiang characteristicsofpdl1inhibitorsfrompeptidestosmallmolecules